PMC9309810_01
Image of chest CT scan. (A,B) chest CT on admission showed multiple miliary nodular lesions that were partially clustered and consolidated diffusely in both lungs; (C,D) After 36 days of treatment, chest CT showed absorption of miliary nodular lesions and new vesicles in the bilateral lung; (E,F) After 56 days of treatment, chest CT showed absorption of miliary nodular lesions and vesicles in the bilateral upper lung.
fphar-13-866027-g001.jpg
PMC9309810_01_fphar-13-866027-g001.jpg
F1
Nevertheless, high-resolution computed tomography (CT) showed multiple miliary nodular lesions partially clustered and diffusely consolidated in both lungs (Figures 1A, B). However, on day 38, after oxygenation, we weaned the patient off mechanical ventilation and observed an improvement in the chest images (Figures 1C,D). The anti-TB treatment regimen was changed to the ethambutol, rifapentine, amikacin, and linezolid regimen to account for potential nervous system adverse reactions to cycloserine and levofloxacin. The patient's symptoms and chest images improved significantly (Figures 1E,F), and she was discharged on day 59.
Monitoring of ACT, APTT, AT-III and platelet in anticoagulant therapy. ACT, activated clotting time; UFH, unfractionated heparin; APTT, active partial thromboplastin time; AT-III, anti-thrombin III; (A) ACT 1 (orange line) showed ACT level during day 1 to day 3 (UHF therapy); ACT 2 (blue line) showed ACT level during day 3 to day 8 ( argatroban therapy); ACT 3 (green line) showed ACT level during day 8 to day 12 ( UHF therapy); ACT 4 (dark blue line) showed ACT level during day 12 to day 27 (argatroban therapy); (B) APTT 1 (orange line) showed APTT level during day 1 to day 3 (UHF therapy); APTT 2 (blue line) showed APTT level during day 3 to day 8 (argatroban therapy); APTT 3 (green line) showed APTT level during day 8 to day 12 ( UHF therapy); APTT 4 (dark blue line) showed APTT level during day 12 to day 27 (argatroban therapy); (C) AT-III 1 (orange line) showed AT-III level during day 1 to day 3 (UHF therapy); AT-III 2 (blue line) showed AT-III level during day 3 to day 8 (argatroban therapy); AT-III 3 (green line) showed AT-III level during day 8 to day 12 ( UHF therapy); AT-III 4 (dark blue line) showed AT-III level during day 12 to day 27 (argatroban therapy); (D) platelet 1 (orange line) showed platelet level during day 1 to day 3 (UHF therapy); platelet 2 (blue line) showed platelet level during day 3 to day 8 (argatroban therapy); platelet 3 (green line) showed platelet level during day 8 to day 12 ( UHF therapy); platelet 4 (dark blue line) showed platelet level during day 12 to day 27 (argatroban therapy).
fphar-13-866027-g002.jpg
PMC9309810_01_fphar-13-866027-g002.jpg
F2
Figure 2 presents the APTT, ACT, AT-III, and platelet count variations throughout the anticoagulant treatments.